{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T10:44:07Z","timestamp":1761734647730,"version":"build-2065373602"},"reference-count":68,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001545","name":"Children&apos;s Tumor Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["1215\u2013200074","739547"],"award-info":[{"award-number":["1215\u2013200074","739547"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medical Genetics"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ejmg.2021.104281","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T12:28:41Z","timestamp":1625488121000},"page":"104281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Lessons learned from drug trials in neurofibromatosis: A systematic review"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0928-4049","authenticated-orcid":false,"given":"Britt A.E.","family":"Dhaenens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9169-4698","authenticated-orcid":false,"given":"Rosalie E.","family":"Ferner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Gareth","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4173-4302","authenticated-orcid":false,"given":"Guenter","family":"Heimann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6127-8909","authenticated-orcid":false,"given":"Cornelia","family":"Potratz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5332-3549","authenticated-orcid":false,"given":"Edwin","family":"van de Ketterij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela M.","family":"Kaindl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2830-1449","authenticated-orcid":false,"given":"Geesje","family":"Hissink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Carton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6700-4768","authenticated-orcid":false,"given":"Marco","family":"Nievo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Legius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7919-8934","authenticated-orcid":false,"given":"Rianne","family":"Oostenbrink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejmg.2021.104281_bib1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.pediatrneurol.2011.06.016","article-title":"Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I study","volume":"45","author":"Acosta","year":"2011","journal-title":"Pediatr. Neurol."},{"issue":"12","key":"10.1016\/j.ejmg.2021.104281_bib2","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1007\/s00405-014-3398-3","article-title":"The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2","volume":"272","author":"Alanin","year":"2015","journal-title":"Eur. Arch. Oto-Rhino-Laryngol."},{"issue":"12","key":"10.1016\/j.ejmg.2021.104281_bib3","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/cncr.29987","article-title":"Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: a report from the Children's Oncology Group","volume":"122","author":"Ater","year":"2016","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ejmg.2021.104281_bib4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/acn3.288","article-title":"A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I","volume":"3","author":"Bearden","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"issue":"16","key":"10.1016\/j.ejmg.2021.104281_bib5","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1001\/jama.2015.2316","article-title":"The platform trial: an efficient strategy for evaluating multiple treatments","volume":"313","author":"Berry","year":"2015","journal-title":"Jama"},{"issue":"5","key":"10.1016\/j.ejmg.2021.104281_bib6","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/neuonc\/nov200","article-title":"Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis","volume":"18","author":"Blakeley","year":"2016","journal-title":"Neuro Oncol."},{"issue":"14","key":"10.1016\/j.ejmg.2021.104281_bib7","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1200\/JCO.2015.64.3817","article-title":"Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2-associated vestibular schwannomas","volume":"34","author":"Blakeley","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ejmg.2021.104281_bib8","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s10897-015-9829-5","article-title":"The impact of neurofibromatosis type 1 on the Health and wellbeing of Australian adults","volume":"24","author":"Crawford","year":"2015","journal-title":"J. Genet. Counsel."},{"issue":"9","key":"10.1016\/j.ejmg.2021.104281_bib9","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s00264-014-2361-7","article-title":"Effectiveness of recombinant human bone morphogenetic protein-7 in the management of congenital pseudoarthrosis of the tibia: a randomised controlled trial","volume":"38","author":"Das","year":"2014","journal-title":"Int. Orthop."},{"key":"10.1016\/j.ejmg.2021.104281_bib10","first-page":"1","article-title":"Identifying challenges in neurofibromatosis: a modified Delphi procedure","author":"Dhaenens","year":"2021","journal-title":"Eur. J. Hum. Genet."},{"issue":"26","key":"10.1016\/j.ejmg.2021.104281_bib11","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ejmg.2021.104281_bib12","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11060-020-03443-6","article-title":"Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience","volume":"147","author":"Esp\u00edrito Santo","year":"2020","journal-title":"J. Neuro Oncol."},{"author":"Eu-Pearl","key":"10.1016\/j.ejmg.2021.104281_bib13"},{"issue":"2","key":"10.1016\/j.ejmg.2021.104281_bib14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.a.33139","article-title":"Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service","volume":"152A","author":"Evans","year":"2010","journal-title":"Am. J. Med. Genet."},{"issue":"11","key":"10.1016\/j.ejmg.2021.104281_bib15","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/jnnp-2018-318538","article-title":"Schwannomatosis: a genetic and epidemiological study","volume":"89","author":"Evans","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.ejmg.2021.104281_bib16","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1136\/bjophthalmol-2017-311305","article-title":"Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the international society of paediatric oncology (siop) low-grade glioma 2004 trial UK cohort","volume":"102","author":"Falzon","year":"2018","journal-title":"Br. J. Ophthalmol."},{"issue":"7","key":"10.1016\/j.ejmg.2021.104281_bib17","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.ejmg.2021.104281_bib18","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/neuonc\/nos076","article-title":"Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis","volume":"14","author":"Fisher","year":"2012","journal-title":"Neuro Oncol."},{"year":"2020","series-title":"Bevacizumab Therapy of Neurofibromatosis Type 2 Associated Vestibular Schwannoma in Japanese Patients","author":"Fujii","key":"10.1016\/j.ejmg.2021.104281_bib19"},{"issue":"2","key":"10.1016\/j.ejmg.2021.104281_bib20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","article-title":"Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas","volume":"122","author":"Goutagny","year":"2015","journal-title":"J. Neuro Oncol."},{"issue":"1","key":"10.1016\/j.ejmg.2021.104281_bib21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ymgme.2008.10.003","article-title":"Clinical research for rare disease: opportunities, challenges, and solutions","volume":"96","author":"Griggs","year":"2009","journal-title":"Mol. Genet. Metabol."},{"issue":"15","key":"10.1016\/j.ejmg.2021.104281_bib22","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmg.2021.104281_bib23","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8685638","article-title":"SARC006: phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 associated chemotherapy-naive malignant peripheral nerve sheath tumors","volume":"2017","author":"Higham","year":"2017","journal-title":"Sarcoma"},{"issue":"7","key":"10.1016\/j.ejmg.2021.104281_bib24","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/pbc.22462","article-title":"Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1","volume":"54","author":"Huttner","year":"2010","journal-title":"Pediatr. Blood Canc."},{"issue":"2","key":"10.1016\/j.ejmg.2021.104281_bib25","first-page":"289","article-title":"Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas","volume":"19","author":"Jakacki","year":"2017","journal-title":"Neuro Oncol."},{"issue":"9","key":"10.1016\/j.ejmg.2021.104281_bib26","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","article-title":"Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"14","author":"Karajannis","year":"2012","journal-title":"Neuro Oncol."},{"issue":"2","key":"10.1016\/j.ejmg.2021.104281_bib27","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/neuonc\/not150","article-title":"Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"16","author":"Karajannis","year":"2014","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejmg.2021.104281_bib28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/B978-0-444-52891-9.00039-7","article-title":"Neurofibromatosis","volume":"111","author":"Korf","year":"2013","journal-title":"Handb. Clin. Neurol."},{"issue":"29","key":"10.1016\/j.ejmg.2021.104281_bib29","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1200\/JCO.2016.68.1585","article-title":"Phase II weekly vinblastine for chemotherapy-na\u00efve children with progressive low-grade glioma: a Canadian pediatric brain tumor consortium study","volume":"34","author":"Lassaletta","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ejmg.2021.104281_bib30","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/s-0034-1368117","article-title":"Pharmacotherapy of attention deficit in neurofibromatosis type 1: effects on cognition","volume":"45","author":"Lidzba","year":"2014","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.ejmg.2021.104281_bib31","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13023-014-0142-4","article-title":"The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial","volume":"9","author":"Lion-Fran\u00e7ois","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ejmg.2021.104281_bib32","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2377-13-131","article-title":"Lovastatin improves impaired synaptic plasticity and phasic alertness in patients with neurofibromatosis type 1","volume":"13","author":"Mainberger","year":"2013","journal-title":"BMC Neurol."},{"issue":"12","key":"10.1016\/j.ejmg.2021.104281_bib33","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1002\/1097-0142(19900615)65:12<2771::AID-CNCR2820651227>3.0.CO;2-J","article-title":"Malignant astrocytic gliomas in children","volume":"65","author":"Marchese","year":"1990","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.ejmg.2021.104281_bib34","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/jso.26153","article-title":"Malignant peripheral nerve sheath tumors in children, adolescents, and young adults: treatment results of five Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry","volume":"122","author":"Meister","year":"2020","journal-title":"J. Surg. Oncol."},{"issue":"7","key":"10.1016\/j.ejmg.2021.104281_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"issue":"4","key":"10.1016\/j.ejmg.2021.104281_bib36","first-page":"281","article-title":"Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation","volume":"3","author":"Morris","year":"2016","journal-title":"Neurooncol Pract"},{"issue":"24","key":"10.1016\/j.ejmg.2021.104281_bib37","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1212\/WNL.0000000000003435","article-title":"Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1","volume":"87","author":"Payne","year":"2016","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.ejmg.2021.104281_bib38","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/MAO.0b013e3181eb328a","article-title":"Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients","volume":"31","author":"Plotkin","year":"2010","journal-title":"Otol. Neurotol."},{"issue":"6","key":"10.1016\/j.ejmg.2021.104281_bib39","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","article-title":"Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients","volume":"33","author":"Plotkin","year":"2012","journal-title":"Otol. Neurotol."},{"issue":"35","key":"10.1016\/j.ejmg.2021.104281_bib40","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1200\/JCO.19.01367","article-title":"Multicenter, prospective, phase II and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular schwannoma","volume":"37","author":"Plotkin","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ejmg.2021.104281_bib41","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/ajmg.a.38680","article-title":"Worries and needs of adults and parents of adults with neurofibromatosis type 1","volume":"176","author":"Rietman","year":"2018","journal-title":"Am. J. Med. Genet."},{"issue":"12","key":"10.1016\/j.ejmg.2021.104281_bib42","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S1470-2045(12)70414-X","article-title":"Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial","volume":"13","author":"Robertson","year":"2012","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.ejmg.2021.104281_bib43","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/1740774515626362","article-title":"Efficiencies of platform clinical trials: a vision of the future","volume":"13","author":"Saville","year":"2016","journal-title":"Clin. Trials"},{"key":"10.1016\/j.ejmg.2021.104281_bib44","first-page":"1","article-title":"What to know about schwannomatosis: a literature review","author":"Schraepen","year":"2020","journal-title":"Br. J. Neurosurg."},{"issue":"1","key":"10.1016\/j.ejmg.2021.104281_bib45","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/jmg.33.1.2","article-title":"Molecular genetics of neurofibromatosis type 1 (NF1)","volume":"33","author":"Shen","year":"1996","journal-title":"J. Med. Genet."},{"issue":"4","key":"10.1016\/j.ejmg.2021.104281_bib46","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40268-018-0248-6","article-title":"Treatment of disfiguring cutaneous lesions in neurofibromatosis-1 with everolimus: a phase II, open-label, single-arm trial","volume":"18","author":"Slopis","year":"2018","journal-title":"Drugs R"},{"issue":"2","key":"10.1016\/j.ejmg.2021.104281_bib47","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF00165101","article-title":"The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group","volume":"7","author":"Sposto","year":"1989","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.ejmg.2021.104281_bib48","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ejmg.2021.104281_bib49","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ejmg.2021.104281_bib50","doi-asserted-by":"crossref","DOI":"10.1186\/s13229-018-0190-z","article-title":"Randomised controlled trial of simvastatin treatment for autism in young children with neurofibromatosis type 1 (SANTA)","volume":"9","author":"Stivaros","year":"2018","journal-title":"Mol. Autism."},{"issue":"3","key":"10.1016\/j.ejmg.2021.104281_bib51","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1177\/0194599818809085","article-title":"Bevacizumab for hearing preservation in neurofibromatosis type 2: emphasis on patient-reported outcomes and toxicities","volume":"160","author":"Sverak","year":"2019","journal-title":"Otolaryngol. Head Neck Surg."},{"issue":"10","key":"10.1016\/j.ejmg.2021.104281_bib52","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/neuonc\/noaa071","article-title":"A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a neurofibromatosis clinical trials consortium study","volume":"22","author":"Ullrich","year":"2020","journal-title":"Neuro Oncol."},{"issue":"17","key":"10.1016\/j.ejmg.2021.104281_bib53","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1200\/JCO.2015.65.3576","article-title":"Distinctive cancer associations in patients with neurofibromatosis type 1","volume":"34","author":"Uusitalo","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ejmg.2021.104281_bib54","first-page":"vdaa075","article-title":"Phase I study of vinblastine in combination with nilotinib in children, adolescents, and young adults with refractory or recurrent low-grade glioma","volume":"2","author":"Vairy","year":"2020","journal-title":"Neurooncol Adv"},{"issue":"11","key":"10.1016\/j.ejmg.2021.104281_bib55","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S1474-4422(13)70227-8","article-title":"Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial","volume":"12","author":"van der Vaart","year":"2013","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.ejmg.2021.104281_bib56","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27833","article-title":"Outcome and prognostic factors in pediatric malignant peripheral nerve sheath tumors: an analysis of the European Pediatric Soft Tissue Sarcoma Group (EpSSG) NRSTS-2005 prospective study","volume":"66","author":"van Noesel","year":"2019","journal-title":"Pediatr. Blood Canc."},{"issue":"10","key":"10.1016\/j.ejmg.2021.104281_bib57","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.3174\/ajnr.A5368","article-title":"Diagnostic accuracy of neuroimaging to delineate diffuse gliomas within the brain: a meta-analysis","volume":"38","author":"Verburg","year":"2017","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"10.1016\/j.ejmg.2021.104281_bib58","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3171\/2015.12.JNS152443","article-title":"Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors","volume":"126","author":"Watson","year":"2017","journal-title":"J. Neurosurg."},{"issue":"6","key":"10.1016\/j.ejmg.2021.104281_bib59","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/pbc.24873","article-title":"Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study","volume":"61","author":"Weiss","year":"2014","journal-title":"Pediatr. Blood Canc."},{"issue":"4","key":"10.1016\/j.ejmg.2021.104281_bib60","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/neuonc\/nou235","article-title":"Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis clinical trials consortium phase II study","volume":"17","author":"Weiss","year":"2015","journal-title":"Neuro Oncol."},{"issue":"5","key":"10.1016\/j.ejmg.2021.104281_bib61","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMra0708126","article-title":"Malignant gliomas in adults","volume":"359","author":"Wen","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ejmg.2021.104281_bib62","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/neuonc\/nou004","article-title":"Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas","volume":"16","author":"Widemann","year":"2014","journal-title":"Neuro Oncol."},{"issue":"9","key":"10.1016\/j.ejmg.2021.104281_bib63","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/pbc.25041","article-title":"Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas","volume":"61","author":"Widemann","year":"2014","journal-title":"Pediatr. Blood Canc."},{"key":"10.1016\/j.ejmg.2021.104281_bib64","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7656747","article-title":"Targeting sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST) in a phase II study of everolimus in combination with bevacizumab (SARC016)","author":"Widemann","year":"2019","journal-title":"Sarcoma"},{"issue":"21 Suppl. 1","key":"10.1016\/j.ejmg.2021.104281_bib65","first-page":"S6","article-title":"Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials","volume":"81","author":"Wolters","year":"2013","journal-title":"Neurology"},{"issue":"7 Suppl. 1","key":"10.1016\/j.ejmg.2021.104281_bib66","first-page":"S4","article-title":"Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials","volume":"87","author":"Wolters","year":"2016","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ejmg.2021.104281_bib67","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1191\/1740774504cn032oa","article-title":"Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals","volume":"1","author":"Wood","year":"2004","journal-title":"Clin. Trials"},{"issue":"3","key":"10.1016\/j.ejmg.2021.104281_bib68","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jid.2018.09.016","article-title":"Absence of efficacy of everolimus in neurofibromatosis 1-related plexiform neurofibromas: results from a phase 2a trial","volume":"139","author":"Zehou","year":"2019","journal-title":"J. Invest. Dermatol."}],"container-title":["European Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769721221001476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769721221001476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:50:44Z","timestamp":1761709844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769721221001476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":68,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1769721221001476"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmg.2021.104281","relation":{},"ISSN":["1769-7212"],"issn-type":[{"type":"print","value":"1769-7212"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lessons learned from drug trials in neurofibromatosis: A systematic review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medical Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmg.2021.104281","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"104281"}}